Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Immunogenicity Persistence At 2, 3, 4, 5, 6 years after booster vaccination of children with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the percentage of subjects with rSBA antibody titres ≥1:8 for each of the four serogroups.
Critère d'inclusion
- Nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis serogroup A, C, W-135 and Y